<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04161690</url>
  </required_header>
  <id_info>
    <org_study_id>13022</org_study_id>
    <nct_id>NCT04161690</nct_id>
  </id_info>
  <brief_title>Evaluation of Dexketoprofen in Total Knee Arthroplasty</brief_title>
  <official_title>Evaluation of Dexketoprofen Given Intravenous or Intrathecal in Postoperative Pain in Patients Undergoing Total Knee Arthroplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>KAT General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>KAT General Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pain is a global public health issue and represents the most common reason for both physician
      consultation and hospital admissions. Dexketoprofen is a new NSAID treating acute
      postoperative pain. The purpose of this study is to evaluate the analgesic effect when it is
      given intravenously or as part of the local infiltration analgesia in patients under spinal
      anesthesia undergoing unilateral total knee arthroplasty.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 6, 2019</start_date>
  <completion_date type="Anticipated">November 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>VAS Score in 8hours after surgery</measure>
    <time_frame>8h</time_frame>
    <description>The visual analogue scale or visual analog scale (VAS) is a psychometric response scale which can be used in questionnaires. It is a measurement instrument for subjective characteristics or attitudes that cannot be directly measured. When responding to a VAS item, respondents specify their level of agreement to a statement by indicating a position along a continuous line between two end-points. 10 describes the worst pain that a person ever imagined.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>VAS Score 24hours after surgery</measure>
    <time_frame>24h</time_frame>
    <description>The visual analogue scale or visual analog scale (VAS) is a psychometric response scale which can be used in questionnaires. It is a measurement instrument for subjective characteristics or attitudes that cannot be directly measured. When responding to a VAS item, respondents specify their level of agreement to a statement by indicating a position along a continuous line between two end-points.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>VAS Score 48hours after surgery</measure>
    <time_frame>48h</time_frame>
    <description>The visual analogue scale or visual analog scale (VAS) is a psychometric response scale which can be used in questionnaires. It is a measurement instrument for subjective characteristics or attitudes that cannot be directly measured. When responding to a VAS item, respondents specify their level of agreement to a statement by indicating a position along a continuous line between two end-points.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total tramadol consumption the first 24hours</measure>
    <time_frame>24h</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Postoperative Pain</condition>
  <condition>Analgesia</condition>
  <arm_group>
    <arm_group_label>Group IV</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dexketoprofen 50mg is given intravenous 10 min before the start of the surgery. Local infiltration analgesia is proceeded by the surgeon with 300mg ropivacaine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group Periarticular</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dexketoprofen 50mg is given as part of the local infiltration analgesia with 300mg ropivacaine. Local infiltration analgesia is proceeded by the orthopedic surgeon.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group P</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Local infiltration analgesia is proceeded by the surgeon with 300mg ropivacaine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexketoprofen Trometamol</intervention_name>
    <description>intravenous dexketoprofen 50mg or intrathecal</description>
    <arm_group_label>Group IV</arm_group_label>
    <arm_group_label>Group Periarticular</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine Hydrochloride 7.5 MG/ML</intervention_name>
    <description>Local Infiltration Analgesia</description>
    <arm_group_label>Group IV</arm_group_label>
    <arm_group_label>Group P</arm_group_label>
    <arm_group_label>Group Periarticular</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  unilateral total knee arthroplasty

          -  accept to enter the study

          -  ASA score I or II

          -  hospitalization for at least 2 days

        Exclusion Criteria:

          -  allergy in any given medications

          -  active gastrointestinal bleeding or other active bleeding

          -  history of peptic ulcer

          -  renal failure

          -  hepatic failure

          -  chronic heart failure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Elena Nikolakopoulou</last_name>
    <phone>+306948569999</phone>
    <email>nikolakopoulou_elena@outlook.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Elena Nikolakopoulou</name>
      <address>
        <city>Athens</city>
        <state>Kifissia</state>
        <zip>14561</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elena Nikolakopoulou</last_name>
      <phone>6948569999</phone>
      <email>nikolakopoulou_elena@outlook.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 9, 2019</study_first_submitted>
  <study_first_submitted_qc>November 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 13, 2019</study_first_posted>
  <last_update_submitted>November 12, 2019</last_update_submitted>
  <last_update_submitted_qc>November 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>KAT General Hospital</investigator_affiliation>
    <investigator_full_name>Elena Nikolakopoulou</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexketoprofen trometamol</mesh_term>
    <mesh_term>Ropivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

